Chemokines, such as CXCL10, promote hepatic inflammation in chronic or acute liver injury through recruitment of leukocytes to the liver parenchyma. The CXCL10 receptor CXCR3, which is expressed on a subset of leukocytes, plays an important part in Th1-dependent inflammatory responses. Here, we investigated the role of CXCL10 in chemically induced liver fibrosis. We used carbon tetrachloride (CCl 4 ) to trigger chronic liver damage in wildtype C57BL/6 and CXCL10-deficient mice. Fibrosis severity was assessed by Sirius Red staining and intrahepatic leukocyte subsets were investigated by immunohistochemistry. We have further analyzed hepatic stellate cell (HSC) distribution and activation and investigated the effect of CXCL10 on HSC motility and proliferation. In order to demonstrate a possible therapeutic intervention strategy, we have examined the anti-fibrotic potential of a neutralizing anti-CXCL10 antibody. Upon CCl 4 administration, CXCL10-deficient mice showed massively reduced liver fibrosis, when compared to wildtype mice. CXCL10-deficient mice had less B-and T lymphocyte and dendritic cell infiltrations within the liver and the number and activity of HSCs was reduced. In contrast, natural killer (NK) cells were more abundant in CXCL10-deficient mice and granzyme B expression was increased in areas with high numbers of NK cells. Further detailed analysis revealed that HSCs express CXCR3, respond to CXCL10 and secrete CXCL10 when stimulated with IFNg. Blockade of CXCL10 with a neutralizing antibody exhibited a significant anti-fibrotic effect. Our data suggest that CXCL10 is a profibrotic factor, which participates in a crosstalk between hepatocytes, HSCs and immune cells. NK cells seem to play an important role in controlling HSC activity and fibrosis. CXCL10 blockade may constitute a possible therapeutic intervention for hepatic fibrosis.
Introduction
Hepatic fibrosis is a scarring response common to most forms of chronic liver injury, which can be caused by pathogens (hepatitis viruses, Leishmania donovani, Schistosoma mansoni), alcohol abuse, chemical toxins, as a side effect of the metabolic syndrome (nonalcoholic steatohepatitis, NASH) or due to autoimmune liver disorders, such as autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) [1e8] . Liver fibrosis is characterized by an accumulation of extracellular matrix (ECM) proteins and a change in the type of ECM from the normal basement membrane-like matrix to a matrix rich in fibrillar collagens. An abnormal ECM composition jeopardizes the continuation of differentiated functions of all resident liver cells and results in cirrhosis, portal hypertension and finally in liver failure [1e3,9] . At the cellular level, noxious agents damage hepatocytes, inducing the recruitment of inflammatory cells and the activation of Kupffer cells, resulting in the release of cytokines, chemokines and growth factors [6, 10, 11] . The primary target cell in this inflammatory milieu is the HSC, which transdifferentiates from a quiescent retinoidstoring mesenchymal cell to an activated myofibroblast that expresses a-smooth muscle actin (aSMA) and is mainly responsible for the accelerated production of ECM in fibrotic tissue [1,3,9e11] . However, HSCs themselves express a multitude of soluble factors and as antigen-presenting cells participate in a complex cellular crosstalk [6, 10, 12] .
An important chemokine responsible for the recruitment and localization of inflammatory cells to sites of tissue damage or infection is CXCL10 (IP10, IFN-inducible protein 10) [13e19]. It is bound by CXCR3, a receptor shared with CXCL4 (PF4, platelet factor 4; a very weak ligand), CXCL9 (Mig, monokine induced by IFNg) and CXCL11 (I-TAC, IFN-inducible T cell a-chemoattractant) [20] , which is expressed on CD4 and CD8 T cells, NK cells, B cells and dendritic cells (DCs) [21e23] . Several studies suggest a role of CXCL10 in the development of intrahepatic inflammation and fibrosis. First, in chronic hepatitis B and C patients, expression of genes encoding CXCL10 and CXCR3 was upregulated and expression levels correlated with disease severity [24e27]. CXCL10 was secreted by hepatocytes in areas of lobular inflammation in close proximity to CXCR3 þ CD8 T cells [25, 27] . Second, CXCL10 serum levels have been found to be increased in patients with AIH [26] . Third, in patients with PBC and their relatives, the plasma level of CXCL10 and the frequency of CXCR3 þ cells were upregulated [26, 28] . Interestingly, CXCL10 expression was apparent in portal areas, where also CXCR3 þ cells, which were primarily CD4 T cells, were found [28] .
In mice, bile duct ligation, Concanavalin A treatment and toxic injury by CCl 4 , D-galactosamine or methylene dianiline led to an increase in CXCL10 mRNA synthesis [29, 30] . CXCL10 induction was also observed after two-third hepatectomy, a procedure which is followed by as strong regenerative response. A direct mitogenic effect of CXCL10 on hepatocytes could not be demonstrated [30] . However, a human fibroblast cell line secreted the potent hepatic mitogen hepatocyte growth factor upon treatment with CXCL10 and mice injected with CXCL10 showed increased CXCR2 expression, a receptor known for its hepatoprotective effect [30e32]. These findings suggest an indirect stimulatory role of CXCL10 in liver regeneration. In contrast, Yoneyama et al. reported an inhibitory effect of CXCL10 on hepatocyte proliferation [33] .
In this study, we sought to investigate the role of cytokines in liver fibrosis. Since concanavalin A or LPS induced liver damage depends on the activation of T cells or B cells/macrophages [34, 35] , we decided to use CCl 4 -mediated liver injury in order to avoid activation of a specific subset of lymphocytes but to induce general hepatotoxicity. In an initial screening for inflammatory factors in CCl 4 -triggered fibrosis, we detected a massive increase in CXCL10 expression. Thus, we used CXCL10-deficient (CXCL10 À/À ) mice and observed that absence of CXCL10 results in a much milder form of fibrosis with reduced numbers of liver infiltrating B-and T lymphocytes, but increased NK cell presence, highlighting the profibrotic role of CXCL10 in chemically induced liver injury.
Material and methods

Mice, CCl 4 administration and antibody treatment
CXCL10
À/À mice are on a C57BL/6 background [16] . Wildtype C57BL/6 mice were purchased from Harlan Netherlands (Horst, Netherlands). Carbon tetrachloride (CCl 4 ) was from Sigma-Aldrich (St. Louis, MO, USA). CCl 4 treatment in 6e8 weeks old animals was performed twice weekly by intraperitoneal (i.p.) injection of 5 ml CCl 4 diluted 1:20 in corn oil. Five animals per group and condition were used. Experiments were performed at least 3 times. The hamster antimurine CXCL10 mAb (1F11, [17] ) was administered at 50 mg or 100 mg in 100 ml PBS per mouse three times a week starting 6 h before the first CCl 4 injection. As control, an isotype-matched hamster IgG Ab (Southern Biotechnology, Birmingham, AL, USA) was used. All animal experiments have been approved by the local Ethics Animal Review Board, Darmstadt, Germany.
HSC isolation
HSCs were isolated from mouse livers by the pronaseecollagenase method and a 12% Nycodenz gradient (Sigma-Aldrich, St. Louis, MO, USA) as described in [36] . Isolated cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine and 1% antibiotic solution at 37 C. HSC purity was determined by Oil red O staining, which showed the typical light microscopic appearance of lipid droplets (Fig. 1B, left panel) .
RNase protection assay (RPA)
Either freshly isolated HSCs were used or HSCs were seeded in 6-well plates in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine and 1% antibiotic solution. The next day, cells were washed with PBS and serum-starved in DMEM supplemented with 1% bovine serum albumin and 1% antibiotic solution for 24 h. Then, cells were stimulated with IFNg (PeproTech, London, UK) for indicated times. Total RNA was isolated using Trizol (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol. Eight micrograms of total RNA was used for hybridization with a 32 P-UTP-labeled multitemplate set containing specific probes for various chemokines (Riboquant, mCK-5, BD Biosciences, San Diego, CA, USA). The RPA was conducted according to the manufacturer's guidelines. The resulting analytical acrylamide gel was scanned using a Pharos imaging system (Bio-Rad, Munich, Germany). Intensity of bands corresponding to protected mRNA was quantified using Quantity One Software (Bio-Rad, Munich, Germany) and GAPDH was a reference gene.
Immunohistochemistry
Livers were harvested at the times indicated, immersed in Tissue-Tek O.C.T. (Sakura Finetek, Zoeterwoude, Netherlands) and quick-frozen on dry ice. Seven mm sections were cut and fixed in EtOH at À20 C and after washing in PBS an avidine-biotin blocking step (Vector laboratories, Burlingame, CA, USA) was included. Primary and biotinylated secondary antibodies (Vector laboratories, Burlingame, CA, USA) were incubated with the sections for 60 min each and color reaction was obtained by sequential incubation with avidine-peroxidase conjugate (Vector laboratories, Burlingame, CA, USA) and diaminobenzidine-hydrogen peroxide. Primary antibodies used were: rat anti-mouse CD4, rat anti-mouse CD8a, rat anti-mouse CD19 and rat anti-mouse CD45R/B220 mAbs (all from BD Biosciences, San Diego, CA, USA), rat anti-mouse F4/80 mAb (AbD Serotec, Raleigh, NC, USA), polyclonal rabbit anti-human desmin antibody (abcam, Cambridge, UK), rabbit anti-granzyme B antibody (abcam, Cambridge, UK), rabbit anti-Ki67 antibody (abcam, Cambridge, UK), biotinylated hamster anti-mouse CD11c mAb (eBioscience, San Diego, CA, USA), goat anti-NKp46 antibody (R&D Systems, Minneapolis, MN, USA) and rabbit anti-mouse collagen I antibody (Chemicon, Temecula, USA). To visualize CXCL10 production in HSCs, starved cells were incubated in culture medium containing 0.5% FCS and 10 ng/ml IFNg for 8 h, then medium was replaced and cells were treated with 10 ng/ml IFNg and 2 mg/ml Brefeldin A for additional 15 h. Cells were fixed in 4% paraformaldehyde and CXCL10 was stained with a polyclonal rabbit anti-mouse CXCL10 antibody (PeproTech, London, UK), as described above. Staining of aSMA was done with a mouse anti-human aSMA mAb (1A4, DakoCytomation, Glostrup, Denmark) and the Vector MOM kit (Vector laboratories, Burlingame, CA, USA). Sirius Red staining was done by incubating EtOH-fixed cryosections for 1 h in Sirius Red solution containing 0.1% saturated picric acid (Electron Microscopy Sciences, Hatfield, PA, USA). Sections were washed in 2 changes of 0.01 N HCl for 2 min, rinsed in water, dehydrated in 3 changes of absolute EtOH for 1 min each, incubated in 2 changes of xylol and mounted in Roti-Histokitt (Roth, Karlsruhe, Germany). Relative fibrosis area, expressed as % of total liver area, was assessed by analyzing 7 liver sections per animal. Fields were acquired at Â10 magnification and then analyzed with the computerized morphometry system Quantity One (Bio-Rad, Munich, Germany). Results are mean AE SEM (n ¼ 7).
Flow cytometry
HSCs isolated from 6 naïve mice or from 6 mice treated with CCl 4 for 4 weeks were kept in culture for 20 h and were then detached and washed. Cells were stained for surface expression of CXCR3 and were subsequently fixed, permeabilized and stained for intracellular GFAP as previously described [37] . APC-conjugated rat anti-mouse CXCR3 mAb was from R&D Systems (Minneapolis, MN, USA) and Alexa488-conjugated anti-GFAP mAb was from Chemicon (Temecula, USA). Samples were acquired using a FACS Canto II flow cytometer (BD Biosciences, Heidelberg, Germany).
Transwell migration assay
Freshly isolated HSCs were seeded in the upper chamber of a Transwell insert (8 mM pore size, Corning Costar, Chorges, France) at 200,000 cells/well in complete culture medium. The lower chamber was filled with medium supplemented with 20 ng/ml recombinant mouse CXCL10 (PeproTech, London, UK). Assays were incubated at 37 C for up to 3 days. Medium AE CXCL10 in the lower chamber was replaced every day. To stop migration, cells were fixed in methanol and stained in crystal violet. Cells on the upper side of the membrane were wiped off with a cotton swap and cells that had migrated through the pores to the underside of the membrane were quantified. Of each filter, pictures of 10 individual fields were taken and cells were counted. Assays were done in duplicates and repeated 3 times. Results are mean AE SD (n ¼ 3) per condition.
Protein immunoblotting
Total protein extracts were prepared in PBS containing 1% Triton X-100 and complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Proteins (100 mg/lane) were resolved on a 10% SDS-polyacrylamide gel. Immunoblots were incubated overnight at 4 C with polyclonal rabbit anti-human desmin antibody (abcam, Cambridge, UK) or rabbit anti-GFAP antibody (DakoCytomation, Glostrup, Denmark) and sequentially with mouse anti-HSP70 mAb (abcam, Cambridge, UK). Alkaline phosphatase-conjugated secondary antibodies (Bio-Rad, Munich, Germany) were visualized with ECF substrate Vistra (Amersham Biosciences, Buckinghamshire, UK) and the Pharos FX Plus imager system (Bio-Rad, Munich, Germany). Livers of 2 wildtype and 2 CXCL10
À/À animals were analyzed.
Serum aminotransferase assays
Activity assays for alanine aminotransferase and aspartate aminotransferase were performed with the RANDOX ALT/AST kit (RANDOX, Crumlin, UK). Sera of 5 mice per group were tested. Results are mean AE SD (n ¼ 5) per condition.
Statistical analysis
The parametric data were analyzed by Student t test. Values of P < 0.05 were considered statistically significant.
Results
CXCL10 promotes liver fibrosis
Our initial studies in C57BL/6 mice showed an upregulation of CXCL10 mRNA in livers of mice that have been exposed to chronic CCl 4 treatment. A kinetic analysis of CXCL10 mRNA expression conducted in HSC enriched fractions obtained from pools of 5 livers of CCl 4 -treated mice per time revealed an up to 10-fold upregulation of CXCL10 at the peak of expression (week 4 of treatment) (Fig. 1A) . Next, we determined whether isolated HSCs (Fig. 1B) have the potential to produce CXCL10 in vitro. To this end, we treated serum-starved cells isolated from wildtype or CXCL10 À/À mice with 10 ng/ml recombinant IFNg and stained for intracellular CXCL10. In contrast to HSCs isolated from CXCL10 À/À mice, wildtype HSCs readily produced CXCL10 within 24 h of stimulation (Fig. 1B) . RNase protection assays revealed that wildtype HSCs expressed small amounts of CXCL10 mRNA constitutively, whereas no CXCL10 signal was detectable in CXCL10 À/À HSCs (Fig. 1C) . Upon IFNg stimulation, wildtype HSCs time-dependently increased CXCL10 mRNA production, resulting in a more than 80-fold increase in CXCL10 message. There was no further increase in signal intensity when 100 ng/ml IFNg were used (Fig. 1C) .
To test the importance of CXCL10 in liver fibrosis, we compared wildtype mice with CXCL10 À/À mice, which both were treated with CCl 4 for 4 weeks. Sirius red stainings revealed that in livers from wildtype mice periportal collagen deposition was substantial and bridging fibrosis was evident ( Fig. 2A) . In contrast, livers from CXCL10 À/À mice only occasionally showed collagen fibers reaching from the periportal area deeper into the liver parenchyma and no signs of emerging bridging fibrosis were seen ( Fig. 2A) was rather weak, indicating that nearly all HSCs were in an inactive state ( Fig. 2B and C) . In livers of wildtype mice, desmin staining was much stronger and the majority of desmin-positive cells was also aSMA-positive ( Fig. 2B and C) . Activated HSCs were found in the perivascular region and extensively penetrated into the parenchyma, explaining the high content of Sirius red stained fibers in these regions ( Fig. 2A) . Thus, our data indicate that CCl 4 treatment triggers an upregulation of CXCL10 in the liver and that CXCL10 plays an important role in chemically induced liver fibrosis. In the absence of CXCL10, fibrosis is less severe. (Fig. 3A) and immunoblotting demonstrated equal amounts of GFAP (marker for quiescent HSC) and desmin expressed in these livers (Fig. 3B) . Hence, livers of naïve (Fig. 3C ). After chronic treatment for 4 weeks, ALT and AST levels were still similar in wildtype and CXCL10 À/À livers (Fig. 3C) . Therefore, reduced fibrosis in CCl 4 -treated CXCL10 À/À livers cannot be explained by lower initial HSC numbers or higher hepatocyte resistance to chemical damage.
Livers of naïve wildtype and CXCL10
Quiescent HSCs express CXCR3 and CXCR3 þ HSCs are frequent in activated populations
HSCs may directly respond to a change in CXCL10 concentrations if they express the CXCL10-specific receptor CXCR3. Using flow cytometry, we tested cell surface expression of CXCR3 in HSCs isolated from livers of naïve control-or CCl 4 -treated wildtype mice. Prior to analysis, HSCs were kept in culture for 20 h. HSC purity was >90% as determined by Oil red O staining (Fig. 1B, left panel) . HSCs were identified by staining for intracellular expression of the HSC marker GFAP [38] . Fig. 3D shows that 8.6% of the analyzed GFAPpositive control HSCs were CXCR3
þ . Interestingly, the number of
þ HSCs increased to 42.4% in cell preparations from livers purified after 4 weeks of CCl 4 treatment (Fig. 3D ). These findings suggest that the frequency of CXCR3-expressing cells is higher in activated HSCs than in quiescent HSCs.
CXCL10 stimulates HSC migration but has not influence on HSC proliferation in vitro
To test whether CXCR3 expression has an influence on HSC migration, we performed chemotaxis assays. To this end, HSCs from control-or CCl 4 -treated mice were isolated and seeded in Transwell migration chambers in the absence or presence of 20 ng/ml recombinant CXCL10. Medium in the lower chamber was replaced every 24 h. Migration was stopped after 1 day or 3 days of incubation and cells that had migrated to the underside of the Transwell membrane were stained and counted. Apparently, CXCL10 triggered increased migration in control HSCs whereas motility of CCl 4 -exposed HSCs was not further amplified by CXCL10 (Fig. 4A) .
Besides migration, CXCL10 could also influence HSC growth. However, when freshly isolated wildtype HSCs were treated with CXCL10, as described in the migration assay, there was no difference in proliferation measurable compared to untreated HSCs (data not shown). Thus, CXCL10 can stimulate migration but not proliferation of HSCs in vitro. To analyze proliferation in vivo, we stained Ki67 in CCl 4 -treated livers of wildtype and CXCL10 À/À mice. In livers of CXCL10 À/À mice, Ki67 staining was mostly seen in hepatocytes and there was no increased proliferation apparent in fibrotic areas (Fig. 4B, left panels) . In livers of wildtype mice, Ki67-positive cells were again hepatocytes but also infiltrating leukocytes (Fig. 4B , right panels, arrowheads). However, Ki67 signal was low in fibrotic regions with small numbers of infiltrating cells in both wildtype (Fig. 4B , right panels, arrows) and CXCL10 À/À mice. This indicates that reduced fibrosis in CXCL10 À/À livers is not due to a lower proliferation capacity of HSCs in the absence of CXCL10, as CXCL10 rather influences HSC migration than HSC growth.
CXCL10 promotes lymphocyte migration into the liver
We next investigated whether the absence of CXCL10 in the knock-out animals may have an effect on the recruitment of CXCR3-expressing immune cells, such as activated T cells, DCs or B (Fig. 5E ). Since B220 is expressed by B lymphocytes as well as by DCs, we also stained with mAbs to CD19 (B cell marker) and CD11c (marker for DCs). Both cell types were less abundant in CXCL10 À/À animals than in wildtype mice (Fig. 5E ). These results indicate that CXCL10 is required for an efficient attraction of B cells, DCs and CD4 T cells.
Anti-CXCL10 therapy protects from CCl 4 -induced liver fibrosis
We then addressed the question whether therapeutic blocking of CXCL10 using a neutralizing anti-CXCL10 mAb could prevent liver fibrosis caused by CCl 4 . Therefore, we injected 50 mg or 100 mg anti-CXCL10 mAb or an isotype-mached control IgG into wildtype animals three times a week starting at 6 h before beginning of CCl 4 administration and lasting for 4 weeks. When analyzing collagen deposition it became apparent that CXCL10 blockade reduced liver fibrosis drastically (Fig. 6A) . Morphometric analysis revealed that hepatic fibrosis decreased from 5.02 AE 0.19% (mean AE SEM) in control livers to 1.05 AE 0.13% in anti-CXCL10 mAb treated livers. In addition, lower numbers of activated HSCs were visible in livers of anti-CXCL10 mAb treated mice (Fig. 6B) . Furthermore, the numbers of infiltrating B220 þ cells and CD4 T cells were strongly reduced in an anti-CXCL10 mAb concentration dependent manner (Fig. 6C) . In fact, 100 mg mAb per mouse were as effective in blocking lymphocyte infiltration as a complete knock-out of the CXCL10 gene. Our data provide evidence that blockade of CXCL10 by a suitable antibody decreases cellular infiltration into the liver, which in turn may reduce fibrosis formation.
Increased NK presence in the absence of CXCL10 protects from liver fibrosis
Since CXCR3 is prominently expressed on NK cells, we further wanted to investigate how CXCL10 influences NK cells during chronic CCl 4 exposure. Interestingly, staining of liver sections with an antibody to the NK marker NKp46 showed that in the absence of CXCL10, either due to genetic deletion (CXCL10 À/À mice; Fig. 7A , middle panel) or antibody neutralization (blocking anti-CXCL10 mAb; Fig. 7A , right panel) the number of infiltrating NK cells is more than 7-fold higher (Fig. 7A) (Fig. 7A, left panel) . However, in CCl 4 -exposed livers of CXCL10 À/À mice or wildtype mice treated with the blocking anti-CXCL10 IgG, aSMA levels were low (Fig. 7A, middle and right panels), correlating with the reduced fibrosis observed in such livers ( Fig. 2A and Fig. 6A ). These findings indicate that CXCL10 À/À mice are protected from CCl 4 -induced liver fibrosis due to a higher rate of NK cell infiltration, which might be responsible for the observed reduction in the frequency of activated HSCs. NK cells kill activated HSCs by a classical mechanism involving perforin and granzyme B [41] . Analyzing consecutive sections of CCl 4 -treated wildtype livers, we detected moderate granzyme B expression but high aSMA levels in areas with NK presence (Fig. 7B, upper panels) . However, in CXCL10 À/À livers, granzyme B expression was high in regions with elevated NK cell content and low numbers of aSMA-positive HSCs. (Fig. 7B , lower panels). Taken together, our results suggest that the lower frequency of activated HSCs observed in CXCL10 À/À livers is due to HSC killing by NK-triggered granzyme B-dependent cytotoxicity, resulting in reduced liver fibrosis. Freshly isolated HSCs from control or CCl 4 -exposed animals were seeded in Transwell chambers. Cells were stimulated with 20 ng/ml CXCL10 or were left untreated (none). Medium was renewed every day. Migration was stopped at indicated time points and cells that had migrated through the Transwell inserts were counted in 10 microscopic fields. Assays were done in duplicates and were repeated 3 times. Data are mean fold induction AE SD (n ¼ 3) with untreated cells set at 1. *P < 0.05 (CXCL10 versus untreated). Consecutive liver sections of CCl 4 -treated wildtype or CXCL10 À/À mice were stained with an antibody to the proliferation marker Ki67 (B) or with Sirius Red (C). Ki67 staining was seen in hepatocytes and strongly in areas with high numbers of infiltrating cells (arrowheads). Ki67 expression was low in regions with high fibrosis but low infiltrates (arrows). Proliferation intensity was similar in wildtype and CXCL10 À/À livers. Scale bar ¼ 100 mm.
Discussion
We report that in the absence of CXCL10, CCl 4 -induced liver fibrosis is less severe and that recruitment of CD4 T cells, DCs and B220 þ cells to the affected liver is strongly reduced. In contrast, the number of infiltrating NK cells is massively increased in both CXCL10 À/À mice as well as in wildtype C57BL/6 mice treated with neutralizing anti-CXCL10 antibody. Furthermore, we show that HSCs express CXCR3 and respond to CXCL10 with an increase in motility. Interestingly, HSCs secrete CXCL10 upon IFNg stimulation.
Our findings suggest that HSCs and a subset of CXCR3 þ immune cells are attracted to sites of liver damage by CXCL10. Relocated HSCs themselves may secrete CXCL10 and thus may subsequently further increase liver infiltration. Previous studies documented that in both man and mouse chronic liver damage by toxic injury, pathogens or autoimmune liver disorders caused an increase in CXCL10 expression. Importantly, these CXCL10 levels correlated with the degree of inflammation [24e30]. Therefore, it is not surprising that we found an increase in CXCL10 mRNA in CCl 4 -exposed mouse livers. Hepatocytes are a major source of CXCL10 in the liver. In chronic hepatitis B and C, as well as in AIH and PBC patients but not in control individuals, lobular hepatocytes expressed CXCL10 and attracted infiltrating CXCR3 þ lymphocytes [25e27]. Furthermore, primary rat hepatocytes secreted CXCL10 after stimulation with IFNg [42] . Importantly, the hepatocyte cell line AML-12 expressed CXCL10 when exposed to CCl 4 [30] , suggesting a direct parenchymal response to cellular injury before inflammatory cells have even reached the site of damage. The finding that mouse HSCs express CXCR3 and respond to CXCL10 with increased motility (our observation and [43] ) might be one reason why we observed a more pronounced clustering of HSCs (stronger desmin staining) in wildtype than CXCL10 À/À portal areas where damaged hepatocytes are predominantly located. Attracted HSCs might then be activated by hepatocytes, leading to upregulation of aSMA expression, which was in our studies indeed stronger in livers of CCl 4 -treated wildtype than CXCL10 À/À mice. Interestingly, we found in addition that HSCs upregulated CXCL10 expression when [51] . Thus, our observation that less CD4 T cells have been found in livers of CXCL10 À/À mice than wildtype animals might be the consequence of B cell absence rather than the cause for reduced fibrosis.
The most intriguing observation of our study might be the increase in NK cell numbers in CCl 4 -exposed CXCL10 À/À livers. It has been previously shown that NK cells express CXCR3 and neutralization of CXCL9 and CXCL10 reduced the recruitment of NK cells to the liver after Hepatitis B virus infection [52] . In Con A induced hepatitis, NK recruitment from the circulation into the liver was macrophage inflammatory protein 1a (MIP-1a) dependent. However, the initial mobilization of NK cells from the spleen into the circulation was triggered by CXCL9 but not by CXCL10 [53] . Given the fact that CXCL9 is a less potent ligand than CXCL10 [54] , one can imagine that in the absence of CXCL10, the effect of CXCL9 is stronger than normal, since competition between both ligands for binding to CXCR3 does no longer apply. Thus, CXCL9 has a higher potential to mobilize NK cells in CXCL10 À/À mice than in wildtype animals. In SCID-BEIGE mice, which lack NK cells (in addition to absence of B cells and T cells), CCl 4 treatment triggered stronger fibrosis than in SCID mice (lacking B-and T cells), again underscoring the anti-fibrotic potential of NK cells [55] . Importantly, NK cell activities negatively correlated with liver fibrosis in patients with chronic hepatitis C infection [40] . The anti-fibrotic effect of NK cells has been demonstrated to be mediated by their capability to specifically kill early-activated but not quiescent HSCs [39, 41, 55] . HSC killing was induced due to upregulation of the NK cell activating ligand retinoic acid early inducible gene 1 (RAE-1) and involved perforin/granzyme B-dependent cytotoxicity [41, 56] . Also in our experiments, activated HSC were the target of granzyme B-linked cell death. Finally, it is an important finding that the treatment with a neutralizing anti-CXCL10 mAb was successful in significantly reducing hepatic fibrosis. Thus, the development of reagents to manipulate the CXCL10/CXCR3 trafficking pathway may be a useful therapeutic strategy to decrease liver fibrosis. However, such reagents need to be highly specific for the CXCL10 pathway, as CXCR3 À/À mice showed increased liver fibrosis when exposed to CCl 4 [57] . In absence of CXCR3, CXCL9 might no longer be able to recruit NK cells and as a consequence activated HSCs would further promote liver fibrosis. Interestingly, the pro-fibrotic role of CXCL10 seems to be liver-specific, as pulmonary fibrosis was more severe in bleomycin-treated CXCL10 À/À mice than in wildtype animals [58] .
In this fibrosis model, CXCL10 inhibited fibroblast migration, whereas leukocyte recruitment was not affected. Thus, depending on the organ, different cell types may be the target of CXCL10 controlled motility resulting in an organ-specific impact of CXCL10 on fibrosis.
In the future it will be important to investigate the role of CXCL10 and the therapeutic potential of its neutralization in hepatic fibrosis occurring as a consequence of autoimmune liver diseases or chronic viral infection, such as Hepatitis B or C virus infection. Novel model systems, like the cytochrome P450 2D6 (CYP2D6) mouse model, which uses an adenovirus expressing the major human autoantigen CYP2D6 to induce autoimmune hepatitis [59] , might be an excellent tool to follow the development of hepatic fibrosis from the initiation of autoimmunity by adenovirus-CYP2D6 infection to the final stages of autoimmune liver destruction.
